Kineta to Present at Jefferies Healthcare Conference
SEATTLE, May 23, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistan ...
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered D ...
Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 24, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address ...
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SEATTLE, April 20, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinic ...
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
SEATTLE, April 17, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 SEATTLE, April 12, 2023 -- Ki ...
Kineta to Present at 22nd Annual Needham Healthcare Conference
SEATTLE, April 03, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, a ...
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
Opened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq ...
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
SEATTLE, March 22, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
SEATTLE, March 08, 2023 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resist ...